Literature DB >> 35294757

Cell-Based Imaging Assay for Detection of Phospholipidosis.

Li Zhang1, Shuaizhang Li1, Menghang Xia2.   

Abstract

Accumulation of lysosomal phospholipids in cells exposed to cationic amphiphilic drugs is characteristic of drug-induced phospholipidosis. The morphological hallmark of phospholipidosis is the appearance of unicentric or multicentric-lamellar bodies when viewed under an electron microscope (EM). The EM method, the gold standard of detecting cellular phospholipidosis, has downsides, namely, low-throughput, high-costs, and unsuitability for screening a large chemical library. This chapter describes a cell-based high-content phospholipidosis assay using the LipidTOX reagent in a high-throughput screening (HTS) platform. This assay has been optimized and validated in HepG2 and HepRG cells, and miniaturized into a 1536-well plate, thus can be used for high-throughput screening (HTS) to identify chemical compounds that induce phospholipidosis.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  HepG2; HepaRG; High-content assay; LipidTOX; Phospholipidosis

Mesh:

Substances:

Year:  2022        PMID: 35294757      PMCID: PMC9438805          DOI: 10.1007/978-1-0716-2213-1_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format.

Authors:  Sampada A Shahane; Ruili Huang; David Gerhold; Ulrich Baxa; Christopher P Austin; Menghang Xia
Journal:  J Biomol Screen       Date:  2013-09-03

2.  Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1).

Authors:  R J Gum; D Hickman; J A Fagerland; M A Heindel; G D Gagne; J M Schmidt; M R Michaelides; S K Davidsen; R G Ulrich
Journal:  Biochem Pharmacol       Date:  2001-12-15       Impact factor: 5.858

3.  Why are most phospholipidosis inducers also hERG blockers?

Authors:  Svetoslav Slavov; Iva Stoyanova-Slavova; Shuaizhang Li; Jinghua Zhao; Ruili Huang; Menghang Xia; Richard Beger
Journal:  Arch Toxicol       Date:  2017-05-27       Impact factor: 5.153

4.  Disobutamide: a model agent for investigating intracellular drug storage.

Authors:  Z Ruben; D C Dodd; K J Rorig; S N Anderson
Journal:  Toxicol Appl Pharmacol       Date:  1989-01       Impact factor: 4.219

5.  Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report.

Authors:  Hiroki Oikawa; Chihaya Maesawa; Ryo Sato; Kanta Oikawa; Hiroyuki Yamada; Seizo Oriso; Sadahide Ono; Akiko Yashima-Abo; Koji Kotani; Kazuyuki Suzuki; Tomoyuki Masuda
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

6.  Aminoglycoside nephrotoxicity.

Authors:  G J Kaloyanides; E Pastoriza-Munoz
Journal:  Kidney Int       Date:  1980-11       Impact factor: 10.612

Review 7.  Emerging mechanisms of drug-induced phospholipidosis.

Authors:  Bernadette Breiden; Konrad Sandhoff
Journal:  Biol Chem       Date:  2019-12-18       Impact factor: 3.915

8.  A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development.

Authors:  A Casartelli; M Bonato; P Cristofori; F Crivellente; G Dal Negro; I Masotto; C Mutinelli; K Valko; V Bonfante
Journal:  Cell Biol Toxicol       Date:  2003-06       Impact factor: 6.691

9.  In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.

Authors:  Paul Nioi; Brad K Perry; Er-Jia Wang; Yi-Zhong Gu; Ronald D Snyder
Journal:  Toxicol Sci       Date:  2007-06-12       Impact factor: 4.849

Review 10.  Review of high-content screening applications in toxicology.

Authors:  Shuaizhang Li; Menghang Xia
Journal:  Arch Toxicol       Date:  2019-10-29       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.